Tue, 03 Feb 2026

Tue, 03 Feb 2026 Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.

  >>